Over the last 2 decades, four major therapeutic approaches have drastically changed the
prognosis in chronic myelogenous leukemia (CML): 1) allogeneic stem cell transplant (SCT); …

The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed
in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem …

Chronic myeloid leukemia (CML) is a stem cell disease characterized by excessive
accumulation of clonal myeloid (precursor) cells in hematopoietic tissues. CML cells display …

▪ Abstract Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder
characterized by the Philadelphia chromosome and resultant production of the constitutively …

During the last four decades, the optimal first-line treatment for chronic myeloid leukemia
(CML) in chronic (stable) phase has progressed from alkylating agents, to hydroxyurea (HU) …

The treatment recommendations for chronic myelogenous leukemia (CML) are evolving
rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr …

Chronic myelogenous leukemia (CML) is a clonal my-eloproliferative disorder molecularly
defined by the BCR-ABL gene and its products. The protein encoded by this chimeric gene …

Abstract Abstract 1126 Poster Board I-148 Background The IRIS study demonstrated
superior safety and efficacy of imatinib (IM) relative to interferon-αa+ cytarabine. Based on …

Over the past 2 decades, our understanding of the pathobiological events underlying
chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and …

Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder that
progresses through distinct phases characterized by progressive loss of the differentiation of …